Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

SUMMARY: In a phase 2 study, continued denosumab treatment for up to 8 years was associated with continued gains in bone mineral density and persistent reductions in bone turnover markers. Denosumab treatment was well tolerated throughout the 8-year study. INTRODUCTION: The purpose of this study is...

Descripción completa

Detalles Bibliográficos
Autores principales: McClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., Miller, P. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536967/
https://www.ncbi.nlm.nih.gov/pubmed/22776860
http://dx.doi.org/10.1007/s00198-012-2052-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536967/
https://www.ncbi.nlm.nih.gov/pubmed/22776860
http://dx.doi.org/10.1007/s00198-012-2052-4

Ejemplares similares